NHI-2 is a potent inhibitor of LDH-A. NHI-2 is an efficient anti-glycolytic agent. NHI-2 has the potential for the research of cancer disease^[1].

335.28

C₁₇H₁₂F₃NO₃

1269802-97-2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Granchi C, et al. Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds. Org Biomol Chem. 2013;11(38):6588-6596.

NHI-2 is a potent inhibitor of LDH-A. NHI-2 is an efficient anti-glycolytic agent. NHI-2 has the potential for the research of cancer disease^[1].

335.28

C₁₇H₁₂F₃NO₃

1269802-97-2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Granchi C, et al. Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds. Org Biomol Chem. 2013;11(38):6588-6596.

NHI-2 is a potent inhibitor of LDH-A. NHI-2 is an efficient anti-glycolytic agent. NHI-2 has the potential for the research of cancer disease^[1].

335.28

C₁₇H₁₂F₃NO₃

1269802-97-2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Granchi C, et al. Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds. Org Biomol Chem. 2013;11(38):6588-6596.